Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.google.com
proteasome inhibitor multiple myeloma - Google News
Get the latest updates from proteasome inhibitor multiple myeloma - Google News directly as they happen.
Follow now < 10 followers
Latest posts
Last updated over 3 years ago
Melflufen Update: A Modern Myeloma Saga - Myeloma Crowd News
over 3 years ago
Melflufen Update: A Modern Myeloma Saga Myeloma Crowd News
CAR-T Cell Therapy May Have 'Big Future' in Relapsed/ Refractory Multiple Myeloma - Curetoday.com
over 3 years ago
CAR-T Cell Therapy May Have 'Big Future' in Relapsed/ Refractory Multiple Myeloma...
Sarclisa Extends Survival in Recent Data and Speeds SubQ Administration in Multiple Myeloma - Myeloma Crowd News
over 3 years ago
Sarclisa Extends Survival in Recent Data and Speeds SubQ Administration in Multiple...
Rough Guide To Targeted Protein Degradation :: In Vivo - In Vivo
over 3 years ago
Rough Guide To Targeted Protein Degradation :: In Vivo In Vivo
Melflufen Update: A Modern Myeloma Saga - Myeloma Crowd News
over 3 years ago
Melflufen Update: A Modern Myeloma Saga Myeloma Crowd News
Sanofi (SNY), Blackstone Ink Deal for Subcutaneous Sarclisa - Nasdaq
over 3 years ago
Sanofi (SNY), Blackstone Ink Deal for Subcutaneous Sarclisa Nasdaq
Here's Why You Should Hold EverQuote (EVER) in Your Portfolio - Nasdaq
over 3 years ago
Here's Why You Should Hold EverQuote (EVER) in Your Portfolio Nasdaq
Itron (ITRI) Wins Deal to Upgrade CUD's Water Infrastructure - Nasdaq
over 3 years ago
Itron (ITRI) Wins Deal to Upgrade CUD's Water Infrastructure Nasdaq
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer - Stockhouse
over 3 years ago
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in...
Costa Reviews Regimens for Patients With Transplant-Eligible and Transplant-Ineligible NDMM - Targeted Oncology
over 3 years ago
Costa Reviews Regimens for Patients With Transplant-Eligible and Transplant-Ineligible NDMM Targeted Oncology
Sanofi Rebounds with $329M Blackstone Infusion for Multiple Myeloma Drug - BioSpace
over 3 years ago
Sanofi Rebounds with $329M Blackstone Infusion for Multiple Myeloma Drug BioSpace
Sanofi Announces €300 Million Collaboration With Blackstone Life Sciences To Advance An Innovative Treatment For Multiple Myeloma - Clinical Leader
over 3 years ago
Sanofi Announces €300 Million Collaboration With Blackstone Life Sciences To Advance An...